The best hid phns of mice and mn gmong ofr astray -Roher~ W. Bums When the great 19th century Scotrish poet Robert Burns wrote perhaps his most memorable line, he was undoubtedly commenting on human nature, nc; medical practice. Nanetheless, the cuurse of medical science, like all human endeavors, ha5 demonstrated that propused solutions atlen lead to unexpected new problems. The case of angioplaaty and restenosis (1) provides perhaps Ihe latest example tolhis well worn paradigm. Although the initial success rate of coronary angioplasty for opening obstructed coronary arteries approaches 95%, restenosis ucculs at the site of an& plasty in 25% to 50% of patients within 6 months, regardless of the type of angioplasty procedure used (2-6).
Given this pathophysiologic mechanism. the problem of controlling restenosis becomes largely the problem of con. trolling the smaotb mu5clc cell re5pon5e to injury. Many approaches have been tried in an titempt tu achiive this. It is our belief, however, that succe55 will largely depend on acquiring a comprehensive knowkdgc ofche 11~4~~ular ml cellular mechanisms responsible far lbe smooul musek cell raspon* IO vascular iqiury and than developing a therapeutic slratcgy bastd w this knowledge. The purpose of this report, thcrcfore, is twofold: finr, (0 review the available information relevant to the5c mechanisms, and oecond, 10 reviaw some of the new mokculnr-based slrategies cuwntly being explored as possible approaches to the control uf corunary rcslen&4 alter angioplssty. Removal of lnbibiw lahnaa. Endothelial cells normally secnte nitric oxide (15,141 and hepatan 5uIfaie proteoglycan (17). both of which inhibit smooth muscle cell proliferation. They also secrete prostacyclin IF'GIJ, which along with nitric oxide, inhibits platelet aggregation. Although it is likelv that the endothelial cells overlying an atheroma are dyslunctional and contribute little to antiproIiferative influences. to the extent they do. their removal by mechanical trauma of angiaplasly would further contribute IO the proliienuive environment.
Muleednr and Cellular Meeban&msa
Wmetbn of sIim&tory ietlwmes. Platelets adhere to the injured vessel well. aggregate end release mitogenic growth faftors aud cytokines W-24). The plutelet response &o causes tbmmbus to develop et the site of injury. which further faeilitetes mulifemtive wocesses (24-28). In addition, the thmmbin &weted dkng the pmce~s of thmmbus development (29) stimulates then pmliferation of smooth muscle c&s (30.31) end is n wtent uctivator of datelets (32,331 and chemoattractant fir monocytes (34). it is be-:ieved to induce the expression of cell adhesion molecules (35.36) end induces cndotheliel cells to express plateletderived growth factor (37) and an inhibito: of plasminogen activator (38). Moreover, the underlying complex atherosclerotic lesion contains macmphages and T ljgmphocyles (39) that when stimulated. exuress cvtokines and emwth &tors W-44). Not only &e s&mth &cle cells th;target of locally released milugenic factors, but in response to injury they them&w express smooth muscle cell genes encoding growth factors, cytokines and the receptors recognizing these ligands (45-65).
Oxygen free radicats are also generated during vascul.x injury 166) and not only damage cell constituents. but also plsy a role in modulating the expression of many genes (67.68), the products of which add to the proliferative effects of vascular injury. As one example of such a pathway. tumor necrosis factor-alpha released by macropheges end smooth muscle cells stimulates production of oxygen free ndicela (69) and activates nuclear factor-kappa B (NF-KB) (701, a multifunctional transcription factor.
The complexity of the response to injury is further increased by the Fact that free radicals and various cytokines increase the expression of cell adhesion molecules, such as intercellular adhesion molecule-l (ICAM-I) and vascular cell adhesion molecule-l (VCAM-I) (71-73). Expressiunofthese and other related molecules leads to the recruitment of mono+zyte-derived mucrophages and neutrophils to tbe injured vessel. which add to the pools of cytokines, growth factors and free radicals already present, thereby further anhestnting and amplifying the response to injury.
Hence, the environment of the vascular wall changes dramaticallv after iniurv. with the rea~ovai of inhibitory factors and the indu&n of proliferation factors. The "et effect of these changes is to stimulate smooth muscle cells to pmliferate and migrate, ultimately leading to the development of a usaintimal mass that in a substantial number of patients can compromise vascular Row. Some of the ceU types and the mitogenic products they release that are involved in the te~cawe to iniurv ere listed in Table I  (74-88 proceed into S phase, the confonnutional state of these molecules conveying an inhibitory function must be altered (by dephosphorylating pS3 and phosphorylating Rb). thereby removing the G, block. One of the major controlling elements regulating progression of cells through the cell cycle are an anay of complexes formed between seveti classes of cyclins and cyclindependent kinases (124.125) (Fig. 3) . Thus. for progression through G, to occur. cvclins D. E and A bind in a sequential m&e; to cyclin-dependent protein kinases (cdks), thereby activatingthe kinase (124-128). The complex formed between cyclin Band the cdd kinase. convenely. is critical for progression fmm the G, thmugh the M phases (129-132). As cells approach the G,IM boundary. cyclin B complexes with cdc2, and after a series of phosphorylations and dephosphorylations. the cdc2lcyclin complex advances the cell into the hi phase. Degradation of the cyclin portion of the complex allows the cell to proceed through the M phase.
Treatment Strategies to hhibit Restenosis Many phammcdogic therapeutic interventions have been
tested in experimental models of vascular injury and in clinical trials. An overview of the efficacy of these diverse therapeutic approaches has been the subject of several excellent reviews (8,133-135). In general. those approaches thal have been tested clinically either have failed despite reported success in various animal models of injury-Induced smooth muscle cell prolifersti~n or have not yet been tested adequately. Hence, it is not clear at this time whether any such attempts will be successful. Hawever. the increasing information with regard to injury-induced molecular events. described earlier. lends itself to the development of new molecular&ased strategies to inhibit smooth muscle cell pmliiemtion and thereby to reduce the likelihood of restenosis.
For example. blaking either the re!case or production of smooth muscle cell mitogens alter injury, the binding of pcptide mitogens to their receptors, the signal transduction pathways resulting from receptor nctivution, ihe expression of the immediate early genes or the factors needed for cell cycle progression all represent distinct targets for molecular intervention. What follows is a selective review of three experimental approaches with which we and many others have heen involved. each of which is derived from the insights gleaned from studying the biology of smooth muscle cell activation. Itemmbbwt cblmerk toxins. We were intrigued by an exprimental approach for the treatment of cancer, which we thought might also be applicable to the restenosis process. This appnxch involves the use of recombinant DNA technology (Fig. 4) We and others (187.188) have tested a repliea~on-d&iettt recombinant adenoviros that contains the marker gene beta-galactosidasc in vascular smooth muscle cells. This vector is highly efficient in infecting and expressing its gene product in rat aortic smooth muscle cells grow in c~lt~rc (187,188). It was also found that uninjured nt carotid artcries showed tienovirus-mediated gc~c transfer limited to the endathelium, whereas ballo&njured arteries exposed to adenovintr a various time points after injury showed high efficiency of beta-galactosidase expression in cells not covered by an intact internal elastic membmtte. Thus, neointimal smooth muscle cells showed high levels of beta-salactosidase expression. whereas toed% smwth mu& cells that arc covered by the internal elastic membrane could only be infected after considerable. injury, which presumably compromises its integrity (187,188).
With the highly efficient ability to transfer genes into arterial smooth muscle cells. it should now he possible to select nume~x cellular targct~ for gene therapy. Among these are growth factors and cytokines and their receptors, components of sigotd transduction pathways necessary for cell proliferation, transcription factors and proteins oecessary for cells to progress through the cell cycle (Fig. I to 3) .
Inhibition of these factors may be made possible by deliveringgenesexpressingeitherantisense transcriptsardominant negative gene products. Smooth muscle cells could also be transfected with genes whose products act as vasodilators, antiplatelet or antithrombotic agents or inhibitors of proliferation. Included among such genes are nitric oxide synthase, tissue-type plasminogen activator, hirudin. prostaglandin H synthasc and the tumor suppression gene ~53. Because free radicals are expressed during injury and are believed to p!ay an important role in the activation of numerous genes (66-60, a strategy to deliver genes to smooth muscle cells encoding such free radical scavenger enzymes as superoxide dismutare or cat&e could also be tested.
A somewhat dilierent strategy would be to express the gene encoding herpes simplex thymidine kinax. When this gene is expressed in mammalian cells, cell proliieration can be inhibited by exwwre of the cells to the drug wciclovir, B nucleoside~anaiogue (189). Herpes simpl&-thymidine kinase preferentially phosphorylates ganciclovir to form a nucleotide analogue that, after being incorporated into the elongating DNA strand. inhibits further DNA synthesis. Thus, delivery of this gene to smooth muscle cells, with subsequent exposure to ganciclovir, represents yet another approach to control of smwth mwcle cell proliferation and therefore the treatment of restenosis. Gmclusions. The major advances being made in understanding the cellular and molecular mechanisms responsible for cell proliferation in general and for the smooth muscle cell response to vascular injury in particular have helped lay the groundwork for cow therapeutic approaches to the Problem ofrestenosis after aneiodastv. We have touched on ogy and targeted gene therapy. These, and undoubtedly other modalities, may be tested in human clinical trials in the not too distant future. Only then can their elficacy and safety be truly evaluated. History would suggest that some will be Gective for tnatine. restenosis but ocrhaw not without .
